Skip to main content
SpringerLink
Log in

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia

  • Clinical Use
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

An Erratum to this article was published on 01 December 1995

Summary

The clinical efficacy and tolerability of simvastatin and fluvastatin were compared in 432 patients with primary hypercholesterolaemia in a multinational, randomised, double-blind trial. Following at least 10 weeks on a lipid-lowering diet, patients continuing to have a total cholesterol level ≥ 6.5 mmol/L and elevated low density lipoprotein (LDL) cholesterol levels received 6 weeks of once-daily treatment with either simvastatin 5mg (n = 109), simvastatin 10mg (n =110), fluvastatin 20mg (n = 105), or fluvastatin 40mg (n = 108). The relative potency rates of simvastatin to fluvastatin in reducing LDL and total cholesterol levels were estimated to be 7.60 and 7.65, respectively. Significantly greater mean reductions in LDL cholesterol levels were found at week 6 with simvastatin 10mg (30%) compared with either fluvastatin 20mg (22%; p < 0.001) or fluvastatin 40mg (26%; p = 0.03). Similarly, LDL cholesterol was lowered more in the simvastatin 5mg group (26%) than in the fluvastatin 20mg group (22%; p = 0.03). No significant difference was seen between simvastatin 5mg and fluvastatin 40mg. Plasma total cholesterol levels were also significantly lower with simvastatin 10mg compared with fluvastatin 20mg (23 vs 16%; p < 0.001) and fluvastatin 40mg (23 vs 19%; p = 0.02), and with simvastatin 5mg compared with fluvastatin 20mg (19 vs 16%; p = 0.01). Simvastatin 5mg and fluvastatin 40mg both lowered total cholesterol levels by 19%. The percentage of patients reaching National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP II) target LDL cholesterol levels after 6 weeks’ treatment with simvastatin 5 or 10 mg/day or fluvastatin 20 or 40 mg/day was 24, 25, 12 and 21%, respectively. Tolerability profiles were generally similar, although significantly more gastrointestinal adverse events occurred in the fluvastatin-treated patients (23 vs 11%). In conclusion, simvastatin 10 mg/day is more effective in lowering total and LDL cholesterol levels than the maximum recommended dose of fluvastatin (40 mg/day), whereas simvastatin 5 mg/day and fluvastatin 40 mg/day showed similar efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 1987; 257: 2176–80

    Article  PubMed  CAS  Google Scholar 

  2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor. JAMA 1986; 256: 2823–8

    Article  PubMed  CAS  Google Scholar 

  3. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia. Implications for diagnosis and therapy. Med Clin North Am 1982; 66: 335–62

    PubMed  CAS  Google Scholar 

  4. Holme I. Cholesterol lowering and the reduction of CHD incidence and total mortality: results from a meta-analysis of randomized trials. Cardiovasc Drugs Ther 1992; 6: 101–2

    Article  PubMed  CAS  Google Scholar 

  5. Law MR, Wald NJ, Wu T, et al. Systemic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363–6

    Article  PubMed  CAS  Google Scholar 

  6. Gould AL, Roussouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274–82

    Article  PubMed  CAS  Google Scholar 

  7. Blankenborn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993; 119: 969–76

    Google Scholar 

  8. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8

    Article  Google Scholar 

  9. The Scandinavian Simvastatin Survival Study Group. Ramdomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  10. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMGCoA reductase inhibitor fluvastatin. Circulation 1993; 87 Suppl. 111: 45–53

    Google Scholar 

  11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502

    PubMed  CAS  Google Scholar 

  12. Peace KE. Biopharmaceutical Statistics for Drug Development. New York: Marcel Deckker, Inc., 1988: 83–118

    Google Scholar 

  13. Expert Panel Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015–23

    Google Scholar 

  14. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther. In press

  15. Dallongeville J, Fruchart JC, Pfister P, et al. The European Fluvastatin Study Group. Fluvastatin reduces levels of plasma Apo B-containing particles and increases those of LpA-I. Am J Med 1994; 96 Suppl. 6A: 32S–36S

    Article  PubMed  CAS  Google Scholar 

  16. Hagen E, Istad H, Ose L, et al. Fluvastatin efficacy and tolerability in comparison and in contribution with cholestyramine. Eur J Clin Pharmacol 1994; 46: 445–9

    Article  PubMed  CAS  Google Scholar 

  17. European Atherosclerosis Society Study Group: Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr, Metab Cardiovasc Dis 1992; 2: 113–54

    Google Scholar 

  18. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994; 73: 12D–17D

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lipid Clinic, National Hospital, Oslo, Norway

    Leiv Ose

  2. Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand

    Russell Scott

  3. Merck & Co., Inc., One Merck Drive, WS2C-35, Whitehouse Station, NJ, 08889-0100, USA

    Leni Grossman

Authors
  1. Leiv Ose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leni Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03259374.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ose, L., Scott, R. & Grossman, L. Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia. Clin. Drug Invest. 10, 127–138 (1995). https://doi.org/10.2165/00044011-199510030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199510030-00001

Keywords

Search

Navigation